Syndax Pharmaceuticals (Waltham, MA) a clinical-stage pharmaceutical company focused on an HDAC inhibitor for solid tumors and hematological tumors, closed a $9M Series A financing, bringing the total round to $49M. Participants include Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures and Pappas Ventures.